These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 24697955)

  • 21. Population pharmacokinetics of mycophenolic acid and dose optimization with limited sampling strategy in liver transplant children.
    Barau C; Furlan V; Debray D; Taburet AM; Barrail-Tran A
    Br J Clin Pharmacol; 2012 Sep; 74(3):515-24. PubMed ID: 22329639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.
    Tett SE; Saint-Marcoux F; Staatz CE; Brunet M; Vinks AA; Miura M; Marquet P; Kuypers DR; van Gelder T; Cattaneo D
    Transplant Rev (Orlando); 2011 Apr; 25(2):47-57. PubMed ID: 21190834
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Generation and Validation of a Limited Sampling Strategy to Monitor Mycophenolic Acid Exposure in Children With Nephrotic Syndrome.
    Benz MR; Ehren R; Kleinert D; Müller C; Gellermann J; Fehrenbach H; Schmidt H; Weber LT
    Ther Drug Monit; 2019 Dec; 41(6):696-702. PubMed ID: 31425441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of mycophenolate mofetil in patients with autoimmune diseases compared renal transplant recipients.
    Neumann I; Haidinger M; Jäger H; Grützmacher H; Griesmacher A; Müller MM; Bayer PM; Meisl FT
    J Am Soc Nephrol; 2003 Mar; 14(3):721-7. PubMed ID: 12595508
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The pharmacokinetics of mycophenolate mofetil in Thai kidney transplant recipients.
    Jirasiritham S; Sumethkul V; Mavichak V; Na-Bangchang K
    Transplant Proc; 2004 Sep; 36(7):2076-8. PubMed ID: 15518751
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mycophenolic acid area under the concentration-time curve is associated with therapeutic response in childhood-onset lupus nephritis.
    Godron-Dubrasquet A; Woillard JB; Decramer S; Fila M; Guigonis V; Tellier S; Morin D; Sordet M; Saint-Marcoux F; Harambat J
    Pediatr Nephrol; 2021 Feb; 36(2):341-347. PubMed ID: 32856157
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil.
    Mourad M; Malaise J; Chaib Eddour D; De Meyer M; König J; Schepers R; Squifflet JP; Wallemacq P
    Clin Chem; 2001 Jan; 47(1):88-94. PubMed ID: 11148182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pre-dose plasma concentration monitoring of mycophenolate mofetil in patients with autoimmune diseases.
    Streicher C; Djabarouti S; Xuereb F; Lazaro E; Legeron R; Bouchet S; Greib C; Breilh D; Pellegrin JL; Viallard JF
    Br J Clin Pharmacol; 2014 Dec; 78(6):1419-25. PubMed ID: 25041114
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mycophenolic acid exposure and complement fraction C3 influence inosine 5'-monophosphate dehydrogenase activity in systemic lupus erythematosus.
    Mino Y; Naito T; Shimoyama K; Ogawa N; Kawakami J
    Ann Clin Biochem; 2017 Jul; 54(4):490-494. PubMed ID: 27538768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimal exposure of mycophenolic acid for induction therapy of childhood lupus nephritis patients: an observational cohort study.
    Zhang L; Chen L; Liu X; Huang Z; Zheng Y; Tang K; Jiang X; Chen P
    Rheumatology (Oxford); 2024 Sep; 63(SI2):SI180-SI187. PubMed ID: 38730553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation.
    Mourad M; Malaise J; Chaib Eddour D; De Meyer M; König J; Schepers R; Squifflet JP; Wallemacq P
    Clin Chem; 2001; 47(7):1241-8. PubMed ID: 11427455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between mycophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune disease on mycophenolate mofetil.
    Neumann I; Fuhrmann H; Fang IF; Jaeger A; Bayer P; Kovarik J
    Nephrol Dial Transplant; 2008 Nov; 23(11):3514-20. PubMed ID: 18586766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation.
    David-Neto E; Pereira Araujo LM; Sumita NM; Mendes ME; Ribeiro Castro MC; Alves CF; Kakehashi E; Romano P; Yagyu EM; Queiroga M; Nahas WC; Ianhez LE
    Pediatr Nephrol; 2003 Mar; 18(3):266-72. PubMed ID: 12644921
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Limited sampling strategies for therapeutic drug monitoring of mycophenolate mofetil therapy in patients with autoimmune disease.
    de Winter BC; Neumann I; van Hest RM; van Gelder T; Mathot RA
    Ther Drug Monit; 2009 Jun; 31(3):382-90. PubMed ID: 19363460
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease.
    Abd Rahman AN; Tett SE; Staatz CE
    Clin Pharmacokinet; 2013 May; 52(5):303-31. PubMed ID: 23475567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pre-transplant mycophenolate mofetil pharmacokinetics in Mexican children.
    Villa M; González R; García-Roca P; Hernández AM; Ortiz L; Castañeda-Hernández G; Medeiros M
    Proc West Pharmacol Soc; 2011; 54():66-8. PubMed ID: 22423584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Defining algorithms for efficient therapeutic drug monitoring of mycophenolate mofetil in heart transplant recipients.
    Kaczmarek I; Bigdeli AK; Vogeser M; Mueller T; Beiras-Fernandez A; Kaczmarek P; Schmoeckel M; Meiser B; Reichart B; Ueberfuhr P
    Ther Drug Monit; 2008 Aug; 30(4):419-27. PubMed ID: 18641552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics and variability of mycophenolic acid from enteric-coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients.
    Hummel M; Yonan N; Ross H; Miller LW; Sechaud R; Balez S; Koelle EU; Gerosa G;
    Clin Transplant; 2007; 21(1):18-23. PubMed ID: 17302587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of concentration-controlled mycophenolate mofetil in proliferative lupus nephritis: an observational cohort study.
    Alexander S; Fleming DH; Mathew BS; Varughese S; Jeyaseelan V; Tamilarasi V; Jacob CK; John GT
    Ther Drug Monit; 2014 Aug; 36(4):423-32. PubMed ID: 25014074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.